Oxford Biomedica, (OXB),...............time to buy.

Prophet, I agree the Beeson Gregory Report is very informative and reassuring if a little out of date now (although subsequent news flow has been positive and therefore reinforces the positive aspects stated in the report).

I was particularly interested in the following:

1) Breakeven possibly as soon as 2005 but may be one off payments before that date.
2)DCF value of 153p and comparative value of 99p (but would now be slightly higher with subsequent good news).
3) Above valuation does NOT include a value for the technology and patent portfolio, or royalty payments on launch, so would expect to see increase in "value" with further collaborations and revenue sources.
4) Even if Trovax does not prove effective, TrovaxDC is a potential backup.
5) The latest version of MetXia is "100 times" more efficient than the original version.
6) OXB are the "world leaders" in the field of nerve regeneration.

Q.

(Not an instruction to buy, sell or hold. DYOR).